Allarity Therapeutics, Inc. (NASDAQ:ALLR – Get Free Report) was the recipient of a large drop in short interest in the month of June. As of June 30th, there was short interest totaling 80,824 shares, a drop of 53.9% from the June 15th total of 175,384 shares. Based on an average trading volume of 144,991 shares, the short-interest ratio is currently 0.6 days. Approximately 0.5% of the shares of the stock are short sold.
Analyst Ratings Changes
ALLR has been the subject of a number of recent analyst reports. Ascendiant Capital Markets boosted their price objective on Allarity Therapeutics from $9.75 to $10.25 and gave the company a “buy” rating in a research report on Monday, June 8th. Wall Street Zen upgraded Allarity Therapeutics to a “hold” rating in a research report on Saturday, May 30th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Allarity Therapeutics in a research note on Monday, April 20th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $10.25.
Read Our Latest Research Report on ALLR
Allarity Therapeutics Price Performance
Allarity Therapeutics (NASDAQ:ALLR – Get Free Report) last posted its earnings results on Friday, May 15th. The company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.05. The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.03 million. As a group, research analysts expect that Allarity Therapeutics will post -0.92 EPS for the current year.
Institutional Trading of Allarity Therapeutics
Several hedge funds have recently modified their holdings of ALLR. Jane Street Group LLC purchased a new position in shares of Allarity Therapeutics in the 2nd quarter valued at about $27,000. XTX Topco Ltd purchased a new stake in shares of Allarity Therapeutics during the fourth quarter worth approximately $36,000. Geode Capital Management LLC increased its stake in shares of Allarity Therapeutics by 49.3% during the second quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock worth $51,000 after buying an additional 16,729 shares during the period. Capital Advisors Inc. OK acquired a new stake in Allarity Therapeutics in the fourth quarter valued at approximately $108,000. Finally, DRW Securities LLC acquired a new stake in Allarity Therapeutics in the fourth quarter valued at approximately $133,000. 11.53% of the stock is currently owned by institutional investors and hedge funds.
About Allarity Therapeutics
Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.
The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.
Featured Stories
- Five stocks we like better than Allarity Therapeutics
- The SK Hynix IPO and 2027’s AI Memory Squeeze
- Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debuts
- Why Welltower’s Growth Story Might Outrun Its Rich Valuation
- One Short- and One Long-Term ETF for Quantum Computing Bulls
Receive News & Ratings for Allarity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allarity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-B3.png){kind=small}